Blood Test Can Rapidly Detect Infection Risk
|
By LabMedica International staff writers Posted on 11 Dec 2013 |

Image: Microfluidic device for six assays under the microscope (Photo courtesy of BioMEMS Resource Center).
A device has been created that is able to detect a person's risk of infection from a drop of blood within minutes, as opposed to current methods, which can take up to two hours.
Neutrophil chemotaxis is critical for defense against infections and its alterations could lead to chronic inflammation and tissue injury and the central role that transient alterations of neutrophil chemotaxis could have on patient outcomes calls for its quantification in the laboratory.
Scientists at the Massachusetts General Hospital (Boston, MA, USA) designed a microfluidic device to study neutrophil chemotaxis from a single droplet of whole blood, which has three main components: a chemokine side chambers (200 × 200 μm), a central whole-blood loading chamber, and migration channels containing red blood cell (RBC) filtering regions.
The filter for each migration channel consists of 10 short channels (length about 75 μm) connected horizontally through an approximately 200-μm-long channel to create 90 degree bending sections capable of trapping the RBCs in order to prevent them from dispersing into the rest of the migration channel. A gradient of the chemoattractant is established along the migration channels by diffusion between the chemoattractant chambers and the central loading chamber.
The assay was validated by comparing neutrophil chemotaxis from finger prick, venous blood and purified neutrophil samples. There was a consistent average velocity of 19 ± 6 μm/minute and directionality of 91.1% between the three sources. The team quantified the variability in neutrophil chemotaxis between healthy donors and found no significant changes over time. The novel whole blood device was also used to monitor neutrophil chemotaxis function in a patient with 24% total body surface area burns over a three-week treatment period.
Daniel Irmia, MD, PhD, an assistant professor at the BioMicro Electrical Mechanical Systems Resource Center (BioMEMS; Boston, MA, USA) and a senior author of the study said, “In many cases, it may not be enough to just count the neutrophils. If neutrophils do not migrate well and cannot reach inside the tissues, this situation could have the same consequences as a low neutrophil count.” The authors concluded that being able to measure patients' risk of infections in a matter of minutes from only a droplet of blood is a significant development and one that will improve current treatment. The study was published on October 2, 2013, in the journal Technology.
Related Links:
Massachusetts General Hospital
BioMEMS Resource Center
Neutrophil chemotaxis is critical for defense against infections and its alterations could lead to chronic inflammation and tissue injury and the central role that transient alterations of neutrophil chemotaxis could have on patient outcomes calls for its quantification in the laboratory.
Scientists at the Massachusetts General Hospital (Boston, MA, USA) designed a microfluidic device to study neutrophil chemotaxis from a single droplet of whole blood, which has three main components: a chemokine side chambers (200 × 200 μm), a central whole-blood loading chamber, and migration channels containing red blood cell (RBC) filtering regions.
The filter for each migration channel consists of 10 short channels (length about 75 μm) connected horizontally through an approximately 200-μm-long channel to create 90 degree bending sections capable of trapping the RBCs in order to prevent them from dispersing into the rest of the migration channel. A gradient of the chemoattractant is established along the migration channels by diffusion between the chemoattractant chambers and the central loading chamber.
The assay was validated by comparing neutrophil chemotaxis from finger prick, venous blood and purified neutrophil samples. There was a consistent average velocity of 19 ± 6 μm/minute and directionality of 91.1% between the three sources. The team quantified the variability in neutrophil chemotaxis between healthy donors and found no significant changes over time. The novel whole blood device was also used to monitor neutrophil chemotaxis function in a patient with 24% total body surface area burns over a three-week treatment period.
Daniel Irmia, MD, PhD, an assistant professor at the BioMicro Electrical Mechanical Systems Resource Center (BioMEMS; Boston, MA, USA) and a senior author of the study said, “In many cases, it may not be enough to just count the neutrophils. If neutrophils do not migrate well and cannot reach inside the tissues, this situation could have the same consequences as a low neutrophil count.” The authors concluded that being able to measure patients' risk of infections in a matter of minutes from only a droplet of blood is a significant development and one that will improve current treatment. The study was published on October 2, 2013, in the journal Technology.
Related Links:
Massachusetts General Hospital
BioMEMS Resource Center
Latest Technology News
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
- Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
- AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
- Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
- Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
- Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







